Immunotherapy in inflammatory bowel disease.
Inflammatory bowel disease affects an increasing number of patients worldwide and is associated with significant morbidity. The dysregulation of the immune system with increased expression of proinflammatory cytokines and increased mucosal expression of vascular adhesion molecules play an important role in its pathogenesis. Strategies targeting TNF-alpha and alpha4-integrin have led to the development of novel therapies for treatment of patients with IBD. This article discusses the efficacy of immunologic agents currently approved for treating Crohn disease and ulcerative colitis and reviews the risks and challenges associated with their use.
Gastroenterology Clinic of Acadiana and Lafayette General Medical Center, Lafayette, LA, USA. jpahluwalia@yahoo.com
Jatinder P
JP
Ahluwalia
D000068879:Adalimumab; D000906:Antibodies / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use; D000068582:Certolizumab Pegol; D000077561:Daclizumab; D004351:Drug Resistance; D005765:Gastrointestinal Agents / Q000276:immunology / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D016867:Immunocompromised Host; D007140:Immunoglobulin Fab Fragments / Q000276:immunology / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D000069285:Infliximab; D007262:Infusions, Intravenous / Q000009:adverse effects; D007412:Intestinal Fistula / Q000188:drug therapy; D007413:Intestinal Mucosa / Q000187:drug effects; D000069442:Natalizumab; D009369:Neoplasms / Q000139:chemically induced; D009894:Opportunistic Infections / Q000209:etiology; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab; D014945:Wound Healing
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; C501380:MLN02 antibody, human; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; C544528:briakinumab; D000069285:Infliximab; D000077561:Daclizumab; D000069549:Ustekinumab; D000068879:Adalimumab; C456519:visilizumab; C502936:tocilizumab; D000068582:Certolizumab Pegol